Product Technical Summary in the Myanmar Dossier

1. Key takeaways

The product technical summary is the core reading material of the Myanmar technical review, and its mandatory elements are five: product name, model, intended use, working principle and material composition. The reviewer’s first impression of the product, and the principal basis for the review judgment, both come from this document.

GRZAN note: the summary’s rejection reasons concentrate in three places — missing elements, inconsistency with the labelling and instructions for use, and intended-use wording that does not match the classification conclusion. The third is the most insidious, because it is a cross-document logical consistency problem that is hard to spot by reading the summary alone. The summary can be remembered as 5 mandatory elements, 3 suggested extensions and 2 high-frequency rejection causes; the suggested extensions are key performance parameters, the boundaries of the applicable scope and contraindicated situations.

• Product name — mandatory element 1;
• Model — mandatory element 2;
• Intended use — mandatory element 3;
• Working principle — mandatory element 4;
• Material composition — mandatory element 5.

Because the device description and the intended use are mandatory at all four risk classes A, B, C and D, no product escapes this requirement, whatever its class. The practical consequence for project planning is that the summary cannot be treated as a low-priority writing task to be finished on the eve of submission: it is the document the reviewer reads first, and the quality of everything that follows is judged against what it says.

2. Legal basis

The summary is a component of the Technical Documents and a mandatory file in the dossier. The table below sets out its elements and the links to classification, consistency and testing obligations. For class II and III devices, the full performance test report must be provided, covering electromagnetic compatibility and biocompatibility, which gives the summary’s material and performance statements a direct evidentiary role rather than a purely descriptive one.

3. Expert insights

Insight 1: the five elements are a minimum list; actual writing must extend them from the reviewer’s perspective. Reviewers need to read the product’s risk points out of the summary, so key performance parameters, the boundaries of the applicable scope and contraindicated situations, although not among the five elements, should also be included. A summary that stops at the minimum invites questions that a fuller summary would have answered in advance, and each such question costs review time that no clarification cycle ever fully recovers.

Insight 2: intended use is the most critical field in the summary. It simultaneously determines the classification conclusion and the boundary of advertising compliance. When writing it, keep the statement broadly consistent with the claims used in other ASEAN markets, so that the same product does not carry contradictory intended-use statements across the region. A mismatch here is particularly costly because it is discovered late, after the classification has been reasoned through the rest of the dossier.

Insight 3: the summary must correspond item by item with the labelling and instructions for use. Any inconsistency is treated by reviewers as a documentation quality defect and triggers a clarification request. A systematic item-by-item comparison before submission is therefore not an optional polish step but a review-passing measure, and the comparison itself should be recorded so the team can show it was done.

Insight 4: the material composition must support the biocompatibility argument. If the materials listed in the summary do not match those in the test report, the reviewer cannot judge the biological safety of the product. The material list is therefore not merely descriptive; it is evidence that connects the summary to the biocompatibility evaluation, and any formulation change must flow through both documents together.

Insight 5: the summary must be readable on a stand-alone basis. Reviewers typically read the summary first and consult the annexes afterwards, so the summary must be self-contained. If it forces the reviewer to hunt through annexes for basic facts, it has already failed part of its purpose before any technical issue is reached, and every such hunt consumes review goodwill that the project may need later.

4. Practical recommendations

• Write the summary element by element against the five mandatory elements. Maintain an element checklist while drafting.
• Include key performance parameters and the boundaries of the applicable scope in the extended content. This raises review efficiency.
• Ensure the intended use matches the classification conclusion and the claims used in other markets. Maintain a cross-market comparison.
• Complete an item-by-item comparison of the summary against the labelling and instructions for use. Cross-check before submission.
• Verify the consistency of the material composition with the test report. Avoid avoidable review challenges.

A useful drafting discipline is to assume the reviewer will read nothing but the summary before forming questions: every sentence that prevents a question from arising is worth more than an annex reference. Drafted this way, the summary becomes the spine of the technical section, with the test reports, the risk management file and the labelling hanging off the statements it makes.

5. Verification checklist

• □ Summary contains product name, model, intended use, working principle and material composition
• □ Key performance parameters and boundaries of the applicable scope have been added
• □ Intended use confirmed consistent with the classification conclusion
• □ Item-by-item comparison of summary with labelling and instructions for use completed
• □ Consistency of material composition with the test report checked
• □ Summary is readable on a stand-alone basis
• □ Summary included in the registration register management

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com